Us Bancorp \De\ Alaunos Therapeutics, Inc. Transaction History

Us Bancorp \De\

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$0.41 - $1.24 $5,727 - $17,321	-13,969 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$0.62 - $1.17 $2,779 - $5,245	4,483 Added 47.26%	13,969 $9,000
Q4 2021 Feb 11, 2022	BUY	$1.09 - $1.89 $6,147 - $10,659	5,640 Added 146.65%	9,486 $10,000
Q3 2021 Nov 10, 2021	BUY	$1.44 - $2.73 $3,412 - $6,470	2,370 Added 160.57%	3,846 $7,000
Q2 2021 Aug 05, 2021	BUY	$2.63 - $3.67 $3,797 - $5,299	1,444 Added 4512.5%	1,476 $4,000
Q1 2021 Apr 28, 2021	BUY	$2.82 - $5.6 $90 - $179	32 New	32 $0
Q3 2020 Nov 10, 2020	SELL	$2.39 - $3.43 $1,195 - $1,715	-500 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$3.98 - $6.2 $1,990 - $3,100	500 New	500 $3,000
Q4 2018 Feb 13, 2019	SELL	$1.61 - $3.62 $17,710 - $39,820	-11,000 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$4.99 - $6.57 $54,890 - $72,270	11,000	11,000 $68,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.